van Waardenburg RCAM - Search Results

1

DNA topoisomerase-targeting chemotherapeutics: what's new?

Cuya SM, Bjornsti MA, van Waardenburg RCAM. Cuya SM, et al. Among authors: van waardenburg rcam. Cancer Chemother Pharmacol. 2017 Jul;80(1):1-14. doi: 10.1007/s00280-017-3334-5. Epub 2017 May 20. Cancer Chemother Pharmacol. 2017. PMID: 28528358 Free PMC article. Review.

2

Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.

van Waardenburg RC, de Jong LA, van Delft F, van Eijndhoven MA, Bohlander M, Bjornsti MA, Brouwer J, Schellens JH. van Waardenburg RC, et al. Mol Cancer Ther. 2004 Apr;3(4):393-402. Mol Cancer Ther. 2004. PMID: 15078982

3

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH. van Waardenburg RC, et al. J Biol Chem. 2004 Dec 24;279(52):54502-9. doi: 10.1074/jbc.M410103200. Epub 2004 Oct 6. J Biol Chem. 2004. PMID: 15471886 Free article.

4

Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.

Jacquiau HR, van Waardenburg RC, Reid RJ, Woo MH, Guo H, Johnson ES, Bjornsti MA. Jacquiau HR, et al. J Biol Chem. 2005 Jun 24;280(25):23566-75. doi: 10.1074/jbc.M500947200. Epub 2005 Apr 6. J Biol Chem. 2005. PMID: 15817450 Free article.

5

Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress.

van Waardenburg RC, Duda DM, Lancaster CS, Schulman BA, Bjornsti MA. van Waardenburg RC, et al. Mol Cell Biol. 2006 Jul;26(13):4958-69. doi: 10.1128/MCB.00160-06. Mol Cell Biol. 2006. PMID: 16782883 Free PMC article.

6

Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway.

Duda DM, van Waardenburg RC, Borg LA, McGarity S, Nourse A, Waddell MB, Bjornsti MA, Schulman BA. Duda DM, et al. J Mol Biol. 2007 Jun 8;369(3):619-30. doi: 10.1016/j.jmb.2007.04.007. Epub 2007 Apr 10. J Mol Biol. 2007. PMID: 17475278 Free PMC article.

7

Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.

He X, van Waardenburg RCAM, Babaoglu K, Price AC, Nitiss KC, Nitiss JL, Bjornsti MA, White SW. He X, et al. Among authors: van waardenburg rcam. J Mol Biol. 2007 Sep 28;372(4):1070-1081. doi: 10.1016/j.jmb.2007.07.055. Epub 2007 Aug 2. J Mol Biol. 2007. PMID: 17707402

8

Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target.

Comeaux EQ, van Waardenburg RC. Comeaux EQ, et al. Drug Metab Rev. 2014 Nov;46(4):494-507. doi: 10.3109/03602532.2014.971957. Epub 2014 Oct 20. Drug Metab Rev. 2014. PMID: 25327705 Review.

9

Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage.

Comeaux EQ, Cuya SM, Kojima K, Jafari N, Wanzeck KC, Mobley JA, Bjornsti MA, van Waardenburg RC. Comeaux EQ, et al. J Biol Chem. 2015 Mar 6;290(10):6203-14. doi: 10.1074/jbc.M114.635284. Epub 2015 Jan 21. J Biol Chem. 2015. PMID: 25609251 Free PMC article.

10

Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.

Cuya SM, Comeaux EQ, Wanzeck K, Yoon KJ, van Waardenburg RC. Cuya SM, et al. Oncotarget. 2016 Dec 27;7(52):86660-86674. doi: 10.18632/oncotarget.13528. Oncotarget. 2016. PMID: 27893431 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters